Leerink Partnrs Issues Optimistic Forecast for ACAD Earnings

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Research analysts at Leerink Partnrs boosted their FY2026 earnings per share estimates for shares of ACADIA Pharmaceuticals in a research note issued to investors on Wednesday, November 6th. Leerink Partnrs analyst M. Goodman now anticipates that the biopharmaceutical company will earn $1.15 per share for the year, up from their previous estimate of $1.09. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.51 per share. Leerink Partnrs also issued estimates for ACADIA Pharmaceuticals’ FY2028 earnings at $2.35 EPS.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.06. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 27.29%. The business had revenue of $250.40 million during the quarter, compared to analyst estimates of $248.83 million. During the same period in the prior year, the firm earned ($0.40) earnings per share. The firm’s revenue was up 18.3% compared to the same quarter last year.

A number of other research firms have also recently issued reports on ACAD. Morgan Stanley cut ACADIA Pharmaceuticals from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $28.00 to $20.00 in a research report on Wednesday, August 7th. Cantor Fitzgerald reduced their price target on ACADIA Pharmaceuticals from $37.00 to $28.00 and set an “overweight” rating for the company in a report on Wednesday, August 7th. UBS Group dropped their price objective on ACADIA Pharmaceuticals from $25.00 to $23.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. Raymond James reiterated a “market perform” rating on shares of ACADIA Pharmaceuticals in a research note on Thursday, October 10th. Finally, HC Wainwright reissued a “buy” rating and issued a $27.00 target price on shares of ACADIA Pharmaceuticals in a research report on Thursday, November 7th. Six investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $25.56.

ACADIA Pharmaceuticals Stock Up 3.5 %

Shares of NASDAQ:ACAD opened at $18.27 on Monday. The firm has a fifty day moving average of $15.48 and a two-hundred day moving average of $15.98. ACADIA Pharmaceuticals has a 12-month low of $14.15 and a 12-month high of $32.59. The firm has a market capitalization of $3.03 billion, a P/E ratio of 23.42 and a beta of 0.38.

Insider Buying and Selling at ACADIA Pharmaceuticals

In other news, CEO Stephen Davis sold 31,747 shares of the company’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $15.28, for a total transaction of $485,094.16. Following the completion of the transaction, the chief executive officer now directly owns 186,555 shares in the company, valued at $2,850,560.40. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other ACADIA Pharmaceuticals news, COO Brendan Teehan sold 9,534 shares of the firm’s stock in a transaction on Monday, August 19th. The shares were sold at an average price of $15.28, for a total value of $145,679.52. Following the sale, the chief operating officer now directly owns 52,177 shares in the company, valued at $797,264.56. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Stephen Davis sold 31,747 shares of the company’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $15.28, for a total transaction of $485,094.16. Following the transaction, the chief executive officer now directly owns 186,555 shares of the company’s stock, valued at $2,850,560.40. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 51,014 shares of company stock valued at $779,494 in the last 90 days. 28.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

Several large investors have recently added to or reduced their stakes in ACAD. Marshall Wace LLP increased its position in shares of ACADIA Pharmaceuticals by 431.1% during the second quarter. Marshall Wace LLP now owns 2,774,353 shares of the biopharmaceutical company’s stock valued at $45,083,000 after purchasing an additional 2,251,940 shares during the period. Millennium Management LLC increased its holdings in ACADIA Pharmaceuticals by 36.2% in the 2nd quarter. Millennium Management LLC now owns 2,937,714 shares of the biopharmaceutical company’s stock valued at $47,738,000 after buying an additional 781,070 shares during the period. Dimensional Fund Advisors LP bought a new stake in ACADIA Pharmaceuticals in the 2nd quarter valued at $10,550,000. Fred Alger Management LLC raised its stake in shares of ACADIA Pharmaceuticals by 19.8% in the 2nd quarter. Fred Alger Management LLC now owns 2,704,439 shares of the biopharmaceutical company’s stock valued at $43,947,000 after buying an additional 446,875 shares in the last quarter. Finally, SG Americas Securities LLC lifted its holdings in shares of ACADIA Pharmaceuticals by 419.8% during the 3rd quarter. SG Americas Securities LLC now owns 517,124 shares of the biopharmaceutical company’s stock worth $7,953,000 after acquiring an additional 417,648 shares during the period. Institutional investors and hedge funds own 96.71% of the company’s stock.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.